摘要目的 研究白细胞分化抗原14(cluster of differentiation antigen 14,CD14)启动子区-260位点单核苷酸多态性(SNP)与影响前列腺癌预后因索的关系.方法 应用聚合酶链反应-连接酶特异检测技术(PCR-LDR)分析168例前列腺癌患者CD14基因-260位点的多态性,比较不同基因型与前列腺癌患者诊断时的前列腺癌特异性抗原(PSA)、Gleason评分和TNM临床分期的关系.结果 CD14-260 T(CT+TT)等位基因与PSA、Gleason评分和TNM临床分期均具有显著的相关性(adjusted OR=4.63,3.09,2.86;95%CI:2.87-9.28,2.12-7.33,2.21-5.31).结论 CD14-260 T(CT+TT)等位基因可能与前列腺癌预后有关,携带CD14-260 T(CT+TT)等位基因的前列腺癌患者可能预后较差.

abstractsObjectives To investigate the potential association between the polymorphism of -260 in the promoter of CD14 gene and prognosis factors (PSA, Gleason score and TNM clinical stage) of prostate cancer.Methods The polymorphism of CD14 -260 sites were analyzed by polymerase chain reaction - ligase detection reaction ( PCR - LDR) technique using genomic DNA isolated from peripheral blood. The association between the risk factors of prostate cancer and different genotypes was evaluated. Results The CD14 - 260T variant allele (CT+TT) was associated with higher PSA value of prostate cancer ( adjusted OR = 4.63; 95% CI = 2.87 - 9.28 ).It was also noted that the CD14 -260T variant allele was associated with higher Gleason score and advanced TNM clinical stage of prostate cancer patients ( adjusted OR = 3.09,2.86; 95% CI = 2.12 - 7.33, 2.21 - 5. 31, respectively). Conclusions The results demonstrated that the CD14 -260 C to T variant influenced the PSSA value,Gleason score and TNM clinical stage of prostate cancer. The CD14 -260T variant might be a risk factor in the prognosis of prostate cancer.